Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron and Tadalafil in Prediabetics
NCT05051436Phase 4Recruiting
- Start
- Dec 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mirabegron and tadalafil in prediabetes (4 arms). Primary endpoint: Oral glucose tolerance test at 14 weeks. Started Dec 2021; status: recruiting.
02
Drugs
mirabegrontadalafil
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT05051436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05051436.